Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2019 Nov 12, 2019
Moleculin Announces New Data Confirms Anti-tumor Efficacy of Annamycin in Both Human and Murine AML Models Oct 29, 2019
Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications Oct 22, 2019
Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery Sep 16, 2019
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019 Aug 16, 2019
Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models Aug 6, 2019
Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort Jul 18, 2019
Moleculin Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation Jul 10, 2019
